SEC EDGARJUN 302 min read$QURE

Abi-Saab Walid sold $67K of QURE

Abi-Saab Walid (Chief Medical Officer) sold 1,434 shares of uniQure N.V. (QURE) at $46.86 on 2026-06-26.

Original reporting

SEC EDGAR · Abi-Saab Walid

Published Jun 30, 2026, 9:06 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 30, 2026, 9:10 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$QURE

Neutral

high confidence

Mentioned

$QURE

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$QURENeutralLow

Why it matters

The newest fact is the CMO’s open-market sale details (shares, price, total value) and post-transaction holdings; it does not include any new operational or financial guidance.

Market read

Traders may note insider selling as a sentiment datapoint, but there is no fundamental catalyst to drive repricing.

What to watch

No 10b5-1 plan is cited, but the article also lacks any follow-on buys, option exercises, or changes in broader insider ownership trends.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-30; sale executed 2026-06-26.

Background

The article is an SEC Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$QURENeutralHigh confidence

Context

uniQure N.V. insider Form 4 shows CMO Abi-Saab Walid sold 1,434 shares at $46.86 on 2026-06-26.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a disclosed sale by an officer, but it provides no new company fundamentals, guidance, or material corporate event.

Market effects

Sector

Minimal—single-company insider transaction without sector-wide catalyst.

Regional

None indicated; filing is company-specific.

Global

None indicated; no deal/regulatory/clinical catalyst mentioned.

Counterpoint

What could challenge this read

The sale could reflect diversification or personal liquidity needs rather than negative expectations, especially with a small absolute value relative to typical institutional flows.

Key entities

issuer
uniQure N.V.
Company whose insider transaction is disclosed via SEC Form 4.
insider
Abi-Saab Walid
Chief Medical Officer who sold shares in an open-market transaction.

Read at source ← All news

OCT 8

$QUREHighAI 9/10

Is uniQure (QURE) Undervalued On New Huntingtons Data And FDA Filing Clarity?

uniQure (QURE) shares have fallen 48% in 30 days and 61.41% in 1 year, despite a 3x increase over 3 years. New Phase I/II data showed slowed Huntington's disease progression. Analysts debate if the stock is undervalued at $23.14, with fair value estimates ranging from $62.42 to $353.71, depending on future earnings and FDA approval.

simplywall.st2 min

OCT 7

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

simplywall.st3 min

OCT 5

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

marketscreener.com1 min

OCT 5

$QUREMed

QURE Downgraded by Barclays -- Price Target Lowered to $28.00

Barclays downgraded uniQure (QURE) from Overweight to Equal-Weight, lowering its price target from $60.00 to $28.00. The company's GF Value™ is $7.94, suggesting it's 195.5% overvalued. uniQure has a GF Score™ of 49/100, indicating mixed financial performance. Analysts cite concerns over financial health and market conditions.

gurufocus.com2 min

OCT 2

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.

investing.com2 min

OCT 1

$QUREHighAI 8/10

uniQure (QURE) Reports New AMT 130 Data As FDA Opens Accelerated Review Path

uniQure (QURE) shared updated Phase I/II data for AMT-130, showing slowed Huntington’s disease progression. The FDA indicated 36-month high-dose data could support accelerated approval. The company focuses on gene therapies for rare conditions, with AMT-130 as a key catalyst.